Urovant Sciences is a biopharmaceutical company focused on developing and commercializing innovative therapies for urological conditions.
Our goal is to be a leading specialty company, recognized and trusted by patients and providers for our commitment to urology.
Urovant Sciences is driving scientific innovation to improve the quality of life for patients with urological conditions that are overlooked, misunderstood or not well managed.
Careers at Urovant Sciences offer exceptional possibilities.
Urovant Sciences is Powered by People and Possibilities™. When you join us, you become part of a world-class team and dynamic culture dedicated to being the best in all that we do and driving the best possible outcomes every day.
Powered by people and possibilities
In The News

May 15, 2022
Urovant Sciences® presents new data from EMPOWUR study, advancing knowledge of the treatment of overactive bladder at the 2022 American Urological Association Meeting
May 13, 2022
Urovant Sciences® Presents Interim Data from Phase 2a Study of Investigational Novel Gene Therapy, URO-902, Supporting Safety, Tolerability, and Efficacy Endpoints at 2022 American Urological Association Meeting
April 19, 2022
Urovant Sciences Announces Publication of EMPOWUR Trial Subgroup Analysis Showing Similar Efficacy for GEMTESA® (Vibegron) 75mg in Dry and Wet Overactive Bladder Populations